Teleflex FY2024 EPS Estimate Boosted by Zacks Research

Teleflex Incorporated (NYSE:TFX) – Equities research analysts at Zacks Research upped their FY2024 earnings per share (EPS) estimates for Teleflex in a research note issued on Thursday, November 7th. Zacks Research analyst R. Department now expects that the medical technology company will earn $13.97 per share for the year, up from their previous estimate of $13.88. The consensus estimate for Teleflex’s current full-year earnings is $13.98 per share. Zacks Research also issued estimates for Teleflex’s Q1 2025 earnings at $3.54 EPS, Q3 2025 earnings at $3.78 EPS, Q4 2025 earnings at $4.22 EPS, FY2025 earnings at $15.27 EPS and Q1 2026 earnings at $4.17 EPS.

TFX has been the subject of several other reports. Mizuho decreased their target price on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. Truist Financial reaffirmed a “hold” rating and issued a $227.00 price target (down previously from $255.00) on shares of Teleflex in a report on Monday, November 4th. Stephens boosted their price objective on Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Needham & Company LLC restated a “hold” rating on shares of Teleflex in a research report on Friday, November 1st. Finally, Royal Bank of Canada decreased their target price on Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $259.25.

Teleflex Price Performance

Shares of TFX opened at $195.55 on Monday. Teleflex has a 1-year low of $194.58 and a 1-year high of $257.85. The firm has a market capitalization of $9.08 billion, a PE ratio of 38.88, a price-to-earnings-growth ratio of 2.00 and a beta of 1.18. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39. The company’s fifty day moving average price is $235.39 and its 200-day moving average price is $223.78.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, October 31st. The medical technology company reported $3.49 earnings per share for the quarter, topping analysts’ consensus estimates of $3.38 by $0.11. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The company had revenue of $764.40 million during the quarter, compared to analyst estimates of $768.68 million. During the same quarter in the prior year, the business earned $3.64 earnings per share. Teleflex’s revenue was up 2.4% on a year-over-year basis.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 15th will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.36 dividend on an annualized basis and a yield of 0.70%. Teleflex’s payout ratio is currently 27.04%.

Insider Activity at Teleflex

In other Teleflex news, Director Stuart A. Randle sold 2,674 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $238.93, for a total transaction of $638,898.82. Following the transaction, the director now directly owns 5,496 shares in the company, valued at approximately $1,313,159.28. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.43% of the stock is owned by insiders.

Institutional Investors Weigh In On Teleflex

Hedge funds and other institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC lifted its position in Teleflex by 12.0% during the first quarter. Janus Henderson Group PLC now owns 5,409,317 shares of the medical technology company’s stock valued at $1,223,424,000 after buying an additional 581,312 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in Teleflex by 564.3% in the second quarter. Point72 Asset Management L.P. now owns 310,484 shares of the medical technology company’s stock valued at $65,304,000 after acquiring an additional 263,743 shares in the last quarter. Cooke & Bieler LP grew its stake in Teleflex by 23.3% in the second quarter. Cooke & Bieler LP now owns 912,797 shares of the medical technology company’s stock worth $191,989,000 after purchasing an additional 172,335 shares in the last quarter. Ceredex Value Advisors LLC bought a new stake in shares of Teleflex in the 2nd quarter valued at approximately $25,550,000. Finally, National Bank of Canada FI raised its holdings in shares of Teleflex by 1,008.2% during the second quarter. National Bank of Canada FI now owns 115,343 shares of the medical technology company’s stock worth $24,388,000 after purchasing an additional 104,935 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.